At the time of writing, Apellis Pharmaceuticals Inc [APLS] stock is trading at $22.0, up 5.01%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The APLS shares have gain 8.21% over the last week, with a monthly amount drifted -10.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Apellis Pharmaceuticals Inc [NASDAQ: APLS] stock has seen the most recent analyst activity on January 21, 2026, when BofA Securities upgraded its rating to a Buy but kept the price target unchanged to $28 for it. On October 15, 2025, Wells Fargo initiated with an Overweight rating and assigned a price target of $32 on the stock. Goldman downgraded its rating to a Sell but stick to its price target of $18 on September 26, 2025. Raymond James downgraded its rating to an Outperform but $52 remained the price target by the analyst firm on May 09, 2025. BofA Securities downgraded its rating to Neutral for this stock on May 09, 2025, but kept the price target unchanged to $23. In a note dated April 29, 2025, Cantor Fitzgerald initiated an Overweight rating and provided a target price of $44 on this stock.
For the past year, the stock price of Apellis Pharmaceuticals Inc fluctuated between $16.10 and $31.17. Currently, Wall Street analysts expect the stock to reach $33.25 within the next 12 months. Apellis Pharmaceuticals Inc [NASDAQ: APLS] shares were valued at $22.0 at the most recent close of the market. An investor can expect a potential return of 51.14% based on the average APLS price forecast.
Analyzing the APLS fundamentals
According to Apellis Pharmaceuticals Inc [NASDAQ:APLS], the company’s sales were 1.02B for trailing twelve months, which represents an 132.98% jump. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at 0.08%, Pretax Profit Margin comes in at 0.05%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.04, Equity is 0.19 and Total Capital is 0.1. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Apellis Pharmaceuticals Inc [NASDAQ:APLS] has a current ratio of 3.54. Further, the Quick Ratio stands at 3.10, while the Cash Ratio is 1.71. Considering the valuation of this stock, the price to sales ratio is 2.74, the price to book ratio is 6.94 and price to earnings (TTM) ratio is 74.10.
Transactions by insiders
Recent insider trading involved Watson David O., Officer, that happened on Jan 22 ’26 when 7832.0 shares were purchased. Officer, Deschatelets Pascal completed a deal on Jan 22 ’26 to buy 5928.0 shares. Meanwhile, Officer Sullivan Timothy Eugene bought 10287.0 shares on Jan 22 ’26.
